{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:25:44Z","timestamp":1762867544534,"version":"3.40.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Infect Dis Rep"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s11908-018-0651-8","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T08:39:55Z","timestamp":1536223195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Moving Past the Routine Use of Macrolides\u2014Reviewing the Role of Combination Therapy in Community-Acquired Pneumonia"],"prefix":"10.1007","volume":"20","author":[{"given":"Geoffrey","family":"Shumilak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy I.","family":"Sligl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,6]]},"reference":[{"issue":"11","key":"651_CR1","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1093\/cid\/cix647","volume":"65","author":"JA Ramirez","year":"2017","unstructured":"\u2022 Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65(11):1806\u201312. https:\/\/doi.org\/10.1093\/cid\/cix647. Prospective population-based cohort study evaluating incidence of CAP in consecutive hospitalized patients at all adult hospitals in Louisville, Kentucky. Calculation of annual population-based incidence of CAP, mortality at 1, 6, and 12\u00a0months following hospitalization, and ecological associations of CAP.","journal-title":"Clin Infect Dis"},{"key":"651_CR2","unstructured":"Rui P, Kang K. National Hospital Ambulatory Medical Care Survey: 2014 Emergency department summary tables. Available from: http:\/\/www.cdc.gov\/nchs\/data\/ahcd\/nhamcs_emergency\/2014_ed_web_tables.pdf."},{"key":"651_CR3","volume-title":"Deaths: final for 2014. National vital statistics reports; vol 65 no4","author":"KD Kochanek","year":"2016","unstructured":"Kochanek KD, Murphy SL, Xu JQ, Tejada-Vera B. Deaths: final for 2014. National vital statistics reports; vol 65 no4. National Center for Health Statistics: Hyattsville; 2016."},{"key":"651_CR4","doi-asserted-by":"crossref","unstructured":"Bennett J, Dolin R, Mandell BM. Douglas and Bennett\u2019s Principles and Practice of Infectious Diseases. Chapter 68: Acute Pneumonia. Philadelphia: Elsevier; 2015. p. 823\u2013828.","DOI":"10.1016\/B978-1-4557-4801-3.00069-2"},{"issue":"5","key":"651_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1155\/2000\/457147","volume":"11","author":"LA Mandell","year":"2000","unstructured":"Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH, The Canadian CAP Working Group. Summary of Canadian Guidelines for the Initial Management of Community-acquired Pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can J Infect Dis. 2000;11(5):237\u201348.","journal-title":"Can J Infect Dis"},{"key":"651_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa.1500245","volume":"373","author":"S Jain","year":"2015","unstructured":"\u2022 Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among U. S. adults. N Engl J Med. 2015;373:415\u201327. https:\/\/doi.org\/10.1056\/NEJMoa.1500245. Active population-based surveillance study of immunocompetent adults hospitalized with community-acquired pneumonia. In addition to conventional diagnostic testing, extensive molecular and serologic testing was employed to characterize causative pathogens and provide contemporary data on the causative agents of CAP. Despite extensive testing, found that no pathogen was detected in the majority of patients. Rhinovirus, influenza, and Streptococcus pneumoniae remained the most common identifiable causes of CAP.","journal-title":"N Engl J Med."},{"key":"651_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11908-015-0507-4","volume":"17","author":"A McFarlane","year":"2015","unstructured":"McFarlane A, Sligl W. The value of macrolide-based regimens for community-acquired pneumonia. Curr Infect Dis Rep. 2015;17:50. https:\/\/doi.org\/10.1007\/s11908-015-0507-4.","journal-title":"Curr Infect Dis Rep"},{"issue":"6858","key":"651_CR8","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/35101544","volume":"413","author":"F Schlunzen","year":"2001","unstructured":"Schlunzen F, Zarivach R, Harms J, et al. Structural basis for the interaction of antibiotics with the peptidyl-transferase centre in eubacteria. Nature. 2001;413(6858):814\u201321. https:\/\/doi.org\/10.1038\/35101544.","journal-title":"Nature"},{"issue":"5","key":"651_CR9","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0022-2836(03)00662-4","volume":"330","author":"T Tenson","year":"2003","unstructured":"Tenson T, Lovmar M, Ehrenberg M. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol. 2003;330(5):1005\u201314.","journal-title":"J Mol Biol"},{"issue":"2","key":"651_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1086\/430906","volume":"41","author":"GV Doern","year":"2005","unstructured":"Doern GV, Richter SS, Miller A, Miller N, Rice C, Heilmann K, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis. 2005;41(2):139\u201348.","journal-title":"Clin Infect Dis"},{"key":"651_CR11","unstructured":"Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. https:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/ (Accessed on April 28, 2018)."},{"issue":"6","key":"651_CR12","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1128\/AAC.48.6.2101-2107.2004","volume":"48","author":"JH Song","year":"2004","unstructured":"Song JH, Jung SI, Ko KS, Kim NY, Son JS, Chang HH, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother. 2004;48(6):2101\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"651_CR13","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.3201\/eid2108.150273","volume":"21","author":"X Zheng","year":"2015","unstructured":"Zheng X, Lee S, Selvarangan R, Qin X, Tang YW, Stiles J, et al. Macrolide-resistant mycoplasma pneumoniae, United States. Emerg Infect Dis. 2015;21(8):1470\u20132.","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"651_CR14","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1128\/AAC.00663-13","volume":"57","author":"Y Kawai","year":"2013","unstructured":"Kawai Y, Miyashita N, Kubo M, Akaike H, Kato A, Nishizawa Y, et al. Nationwide surveillance of macrolide-resistant mycoplasma pneumoniae infection in pediatric patients. Antimicrob Agents Chemother. 2013;57(8):4046\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"651_CR15","first-page":"169","volume":"1","author":"BK Rubin","year":"2000","unstructured":"Rubin BK, Tamaoki J. Macrolide antibiotics as biological response modifiers. Curr Opin Investig Drugs. 2000;1(2):169\u201372.","journal-title":"Curr Opin Investig Drugs"},{"issue":"9","key":"651_CR16","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1183\/09031936.95.08091451","volume":"8","author":"OA Khair","year":"1995","unstructured":"Khair OA, Devalia JL, Abdelaziz MM, Sapsford RJ, Davies RJ. Effect of erythromycin on Haemophilus influenzae endotoxininduced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J. 1995;8(9):1451\u20137.","journal-title":"Eur Respir J"},{"issue":"6","key":"651_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/BF01488805","volume":"20","author":"R Anderson","year":"1996","unstructured":"Anderson R, Theron AJ, Feldman C. Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation. 1996;20(6):693\u2013705.","journal-title":"Inflammation"},{"issue":"5","key":"651_CR18","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1128\/AAC.48.5.1581-1585.2004","volume":"48","author":"M Desaki","year":"2004","unstructured":"Desaki M, Okazaki H, Sunazuka T, Omura S, Yamamoto K, Takizawa H. Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kappa B activation. Antimicrob Agents Chemother. 2004;48(5):1581\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"651_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.antiviral.2017.05.008","volume":"144","author":"N Lee","year":"2017","unstructured":"Lee N, Wong C, Chan M, Yeung E, Tam W, Tsang O, et al. Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: a randomized controlled trial. Antivir Res. 2017;144:48\u201356.","journal-title":"Antivir Res"},{"issue":"3","key":"651_CR20","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1093\/jac\/dkr520","volume":"67","author":"A. Kovaleva","year":"2011","unstructured":"Kovaleva A, Remmelts HHF, Rijkers GT, Hoepelman AIM, Biesma DH, Oosterheert JJ. Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review. J Antimicrob Chemother. 67(3):530\u201340. https:\/\/doi.org\/10.1093\/jac\/dkr520.","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"651_CR21","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1086\/511159","volume":"44 Suppl 2","author":"LA Mandell","year":"2007","unstructured":"Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27\u201372.","journal-title":"Clin Infect Dis"},{"key":"651_CR22","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1136\/thx.2009.121434","volume":"64 Suppl 3","author":"WS Lim","year":"2009","unstructured":"Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64 Suppl 3:iii1\u201355. https:\/\/doi.org\/10.1136\/thx.2009.121434.","journal-title":"Thorax"},{"key":"651_CR23","doi-asserted-by":"publisher","first-page":"g6722","DOI":"10.1136\/bmj.g6722","volume":"349","author":"E Sinan","year":"2014","unstructured":"Sinan E, Celia P, Bernard H, Mark W. Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance. BMJ. 2014;349:g6722. https:\/\/doi.org\/10.1136\/bmj.g6722.","journal-title":"BMJ"},{"issue":"21","key":"651_CR24","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1001\/archinte.159.21.2562","volume":"159","author":"Patrick P. Gleason","year":"1999","unstructured":"Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 159:1999, 2562\u201372.","journal-title":"Archives of Internal Medicine"},{"key":"651_CR25","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1378\/chest.119.5.1420","volume":"119","author":"PM Houck","year":"2001","unstructured":"Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest. 2001;119:1420\u20136.","journal-title":"Chest"},{"key":"651_CR26","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1345\/aph.19174","volume":"34","author":"V Dudas","year":"2000","unstructured":"Dudas V, Hopefl A, Jacobs R, Guglielmo BJ. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother. 2000;34:446\u201352.","journal-title":"Ann Pharmacother"},{"key":"651_CR27","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1378\/chest.123.5.1503","volume":"123","author":"RB Brown","year":"2003","unstructured":"Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest. 2003;123:1503\u201311.","journal-title":"Chest"},{"key":"651_CR28","doi-asserted-by":"publisher","unstructured":"Gardiner SJ, Gavranich JB, Chang AB. Antibiotics for community-acquired lower respiratory tract infections secondary to in children. Cochrane Database Syst Rev 2015, (1):CD004875. https:\/\/doi.org\/10.1002\/14651858.CD004875.pub5.","DOI":"10.1002\/14651858.CD004875.pub5"},{"key":"651_CR29","unstructured":"van Werkhoven CH, Postma DF, Oosterheert DF, Bonten MJM. Antibiotic treatment of moderate-severe community-acquired pneumonia: design and rationale of a multicenter cluster-randomized cross-over trial. Neth J Med. 2014;72(3)"},{"key":"651_CR30","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1378\/chest.128.2.940","volume":"128","author":"K Weiss","year":"2005","unstructured":"Weiss K, Tillotson GS. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. Chest. 2005;128:940\u20136.","journal-title":"Chest"},{"key":"651_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.idc.2012.11.005","volume":"27","author":"TM File Jr","year":"2013","unstructured":"File TM Jr, Marrie TJ. Does empiric therapy for atypical pathogens improve outcomes for patients with CAP? Infect Dis Clin N Am. 2013;27:99\u2013114.","journal-title":"Infect Dis Clin N Am"},{"key":"651_CR32","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","volume":"366","author":"W Ray","year":"2012","unstructured":"Ray W, Murray K, Hall K, Arbogast P, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366:1881\u201390. https:\/\/doi.org\/10.1056\/NEJMoa1003833.","journal-title":"N Engl J Med"},{"issue":"1","key":"651_CR33","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1128\/AAC.01820-15","volume":"60","author":"J Wieczorkiewicz","year":"2016","unstructured":"Wieczorkiewicz J, Lopansri B, Cheknis A, Osmolski J, Hect D, Gerdin D, et al. Fluoroquinolone and macrolide exposure predict Clostridium difficile infection with the highly fluorquinolone and macrolide-resistant epidemic C. difficile strain BI\/NAP1\/027. Antimicrob Agents Chemother. 2016;60(1):418\u201323.","journal-title":"Antimicrob Agents Chemother"},{"key":"651_CR34","first-page":"CD004418","volume":"9","author":"N Eliakim-Raz","year":"2012","unstructured":"Eliakim-Raz N, Robenshtok E, Shefet D, et al. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev. 2012;9:CD004418.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"651_CR35","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/cid\/cis414","volume":"55","author":"L Asadi","year":"2012","unstructured":"Asadi L, Sligl WI, Eurich DT, Colmers IN, Tjosvold L, Marrie TJ, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2012 Aug;55(3):371\u201380. https:\/\/doi.org\/10.1093\/cid\/cis414.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"651_CR36","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","volume":"174","author":"N Garin","year":"2014","unstructured":"\u2022\u2022 Garin N, Genn\u00e9 D, Carballo S, Chuard C, Eich G, Hugli O, et al. \u03b2-Lactam monotherapy vs \u03b2-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med. 2014;174(12):1894\u2013901. https:\/\/doi.org\/10.1001\/jamainternmed.2014.4887. Evaluated the non-inferiority of beta-lactam monotherapy compared with beta-lactam\/macrolide combination therapy in moderately severe CAP in an open-label, multicenter, non-inferiority randomized control trial. Failed to meet primary outcome and demonstrate non-inferiority of beta-lactam monotherapy in moderately severe community-acquired pneumonia. Subgroup analyses revealed equivalent outcomes in patients with mild to moderate CAP (PSI 1-3) but worse outcomes in patients managed with beta-lactam monotherapy and severe CAP. Secondary outcomes were equivalent between the two groups.","journal-title":"JAMA Intern Med"},{"key":"651_CR37","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1056\/NEJMoa1406330","volume":"372","author":"DF Postma","year":"2015","unstructured":"\u2022\u2022 Postma DF, van Werkhoven CH, van Elden LJR, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. (CAP-START). N Engl J Med. 2015;372:1312. Multi-center cluster-randomized, crossover, non-inferiority trial conducted at 7 hospitals in the Netherlands to determine if empiric therapy for CAP with beta-lactam monotherapy was non-inferior to combination beta-lactam\/macrolide therapy or a respiratory fluoroquinolone. 90-day all-cause mortality was lowest in the beta-lactam monotherapy arm. Adjusted comparisons for 90-day all-cause mortality favored beta-lactam monotherapy with a 1.9% lower risk of death when compared to macrolide combination therapy. Time to oral antibiotic de-escalation, length of hospital stay, and occurrence of complications during hospital stay were not significantly different between the groups.","journal-title":"N Engl J Med"},{"key":"651_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.rmed.2017.06.012","volume":"129","author":"CH van Werkhoven","year":"2017","unstructured":"\u2022\u2022 van Werkhoven CH, van de Garde EMW, Oosterheert JJ, Postma DF, Bonten MJM. Atypical coverage in community-acquired pneumonia after outpatient beta-lactam monotherapy. Respir Med. 2017;129:145\u201351. https:\/\/doi.org\/10.1016\/j.rmed.2017.06.012. Evaluation of outcomes in a subset of 179 patients from the CAP-START Trial that had previous beta-lactam exposure prior to hospitalization. Compared thirty-day mortality, hospital length of stay, and frequency of treatment escalations between patients that were continued on beta-lactam monotherapy and patients that received beta-lactams and atypical coverage. No significant differences between groups with respect to 30-day mortality and hospital length of stay were identified.","journal-title":"Respir Med"},{"key":"651_CR39","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1164\/rccm.200311-1578OC","volume":"170","author":"LM Baddour","year":"2004","unstructured":"Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004;170:440\u20134.","journal-title":"Am J Respir Crit Care Med"},{"key":"651_CR40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.rmed.2018.05.020","volume":"140","author":"FW Arnold","year":"2018","unstructured":"Arnold FW, Lopardo G, Wiemken TL, Kelley R, Peyrani P, Mattingly WA, et al. Macrolide therapy is associated with lower mortality in community-acquired bacteremic pneumonia. Respir Med. 2018;140:115\u201321. https:\/\/doi.org\/10.1016\/j.rmed.2018.05.020.","journal-title":"Respir Med"},{"issue":"2","key":"651_CR41","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/CCM.0b013e3182a66b9b","volume":"42","author":"WI Sligl","year":"2014","unstructured":"Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med. 2014;42(2):420\u201332. https:\/\/doi.org\/10.1097\/CCM.0b013e3182a66b9b.","journal-title":"Crit Care Med"}],"container-title":["Current Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11908-018-0651-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-018-0651-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-018-0651-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:11:58Z","timestamp":1744175518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11908-018-0651-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,6]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["651"],"URL":"https:\/\/doi.org\/10.1007\/s11908-018-0651-8","relation":{},"ISSN":["1523-3847","1534-3146"],"issn-type":[{"type":"print","value":"1523-3847"},{"type":"electronic","value":"1534-3146"}],"subject":[],"published":{"date-parts":[[2018,9,6]]},"assertion":[{"value":"6 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Geoffrey Shumilak and Wendy Sligl declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"45"}}